The role of 123I-diagnostic imaging in the follow-up of patients with differentiated thyroid carcinoma as compared to 131I-scanning: avoidance of negative therapeutic uptake due to stunning.

The role of 123I-diagnostic imaging in the follow-up of patients with differentiated thyroid carcinoma as compared to 131I-scanning: avoidance of negative therapeutic uptake due to stunning.

OBJECTIVE: Some patients with relapsed differentiated thyroid cancer may show rising thyroglobulin (Tg) levels despite a lack of 131I uptake on routine whole body imaging. A significant proportion of these patients, after therapy doses of 131I, may demonstrate positive 131I uptake with a subsequent...

Full description

Bibliographic Details
Main Authors:	Siddiqi, A, Foley, R, Britton, K, Sibtain, A, Plowman, P, Grossman, AB, Monson, J, Besser, G
Format:	Journal article
Language:	English
Published:	2001

Similar Items

I-123 imaging for the prediction of I-131 therapy for recurrent differentiated thyroid cancer, RDTC, when I-131 tracer is negative but raised thyroglobulin, Tg
by: Britton, K, et al.
Published: (1999)

The management of differentiated thyroid cancer using 123I for imaging to assess the need for 131I therapy.
by: Ali, N, et al.
Published: (2006)

Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG].
by: Mukherjee, J, et al.
Published: (2001)

Stunning in post 131 I therapy scans after low-dose 131 I diagnostic whole body scans with differentiated thyroid cancer in the Indian patient population: Critical importance of interval between the two scans
by: Nishikant A Damle, et al.
Published: (2012-01-01)

Ocular metastases secondary to carcinoid tumors: the utility of imaging with [(123)I]meta-iodobenzylguanidine and [(111)In]DTPA pentetreotide.
by: Isidori, A, et al.
Published: (2002)

Impact of thyroiditis on 131I uptake during ablative therapy for differentiated thyroid cancer
by: Eugenie S Lim, et al.
Published: (2019-05-01)

Treatment of metastatic pheochromocytoma and paraganglioma with I-131-meta-iodobenzylguanidine (MIBG)
by: Kaltsas, G, et al.
Published: (2003)

Correlation between remnant thyroid gland I-131 uptake and serum thyroglobulin levels: can we rely on I-131 whole body scans?
by: Sang Hyun Hwang, et al.
Published: (2024-01-01)

Carcinoid tumours presenting as breast cancer: the utility of radionuclide imaging with 123I-MIBG and 111In-DTPA pentetreotide.
by: Kaltsas, G, et al.
Published: (1998)

A Neck-Thyroid Phantom with Small Sizes of Thyroid Remnants for Postsurgical I-123 and I-131 SPECT/CT Imaging
by: Konstantinos Michael, et al.
Published: (2023-04-01)

Treatment of malignant phaeochromocytoma, paraganglioma and carcinoid tumours with 131I-metaiodobenzylguanidine.
by: Bomanji, J, et al.
Published: (1993)

The influence of thionamides on intra-thyroidal uptake of 131I during radioiodine-131 treatment of Graves’ disease
by: Christian Happel, et al.
Published: (2023-12-01)

NMR-ON MEASUREMENTS OF I-123, I-124, I-131 IN NICKEL
by: Ohya, S, et al.
Published: (1992)

Thyroid [123I]MIBG uptake in Parkinson’s disease and diabetes mellitus
by: Tatyana D. Fedorova, et al.
Published: (2023-06-01)

Determination of kinetic parameters for 123-I thyroid uptake in healthy Japanese
by: Kusuhara Hiroyuki, et al.
Published: (2017-01-01)

Semi-quantitative assessment of diffuse hepatic uptake seen in I-131 scans – an indicator of functioning thyroid tissue and disease burden in differentiated thyroid cancer
by: Prasanta K. Pradhan, et al.
Published: (2019-04-01)

Sequelae and survivorship in patients treated with 131 I-MIBG therapy
by: Sze, W, et al.
Published: (2013)

Sequelae and survivorship in patients treated with (131)I-MIBG therapy.
by: Sze, W, et al.
Published: (2013)

Unusual sites of metastatic and benign I 131 uptake in patients with differentiated thyroid carcinoma
by: Shanmuga S Palaniswamy, et al.
Published: (2018-01-01)

Localization of neuroendocrine tumours and insulinomas using radiolabelled somatostatin analogues, 123I-Tyr3-octreotide and 111In-pentatreotide.
by: Ur, E, et al.
Published: (1993)

The Value of Pre-Ablative I-131 Scan for Clinical Management in Patients With Differentiated Thyroid Carcinoma
by: Trynke van der Boom, et al.
Published: (2021-05-01)

Incidental detection of acquired unilateral nasolacrimal duct obstruction on I-131 whole body scan following I-131 therapy for thyroid cancer: a case report
by: Warda Ahmad, et al.
Published: (2023-07-01)

Aplicaciones clínicas del radioyodo 131 (I131) en las enfermedades del tiroides Clinical applications of radioiodine 131 (I131) in the thyroid diseases
by: Levi González Rivero, et al.
Published: (2012-12-01)

RADIONUCLIDE SCANNING WITH I-123 IN GRAVES DISEASE
by: Putu Diah Vedayanti, et al.
Published: (2014-01-01)

Stereotactic radiosurgery XVI: a treatment for previously irradiated pituitary adenomas.
by: Swords, F, et al.
Published: (2003)

Incremental value of post-high dose therapy I-131 scan over pre.therapy diagnostic I-131 scan in patients with differentiated thyroid cancer: Experience from a tertiary care centre in South India
by: Chandra Teja Reddy Singareddy, et al.
Published: (2020-01-01)

The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors.
by: Kaltsas, G, et al.
Published: (1998)

In Thyroidectomized Thyroid Cancer Patients, False-Positive I-131 Whole Body Scans Are Often Caused by Inflammation Rather Than Thyroid Cancer
by: Yana Basis Garger MD, et al.
Published: (2016-02-01)

131I-induced changes in rat thyroid gland function
by: V. Torlak, et al.
Published: (2007-08-01)

Transcriptional response to 131I exposure of rat thyroid gland.
by: Nils Rudqvist, et al.
Published: (2017-01-01)

Gamma knife radiosurgery: a safe and effective salvage treatment for pituitary tumours not controlled despite conventional radiotherapy.
by: Swords, F, et al.
Published: (2009)

123I-Interleukin-2: biochemical characterization and in vivo use for imaging autoimmune diseases.
by: Signore, A, et al.
Published: (2003)

Internal exposure levels of thyroid 131I in nuclear medical staff
by: Bin WANG, et al.
Published: (2023-04-01)

123I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation.
by: Bhatia, K, et al.
Published: (2008)

Treatment of solitary, autonomously-functioning, non-toxic thyroid nodules with I131 Adenema tiroideo autónomo no tóxico tratamiento con I131
by: Federico Uribe Londoño, et al.
Published: (1991-03-01)

Successful treatment of childhood-onset Cushing's disease is associated with persistent reduction in growth hormone secretion.
by: Carroll, P, et al.
Published: (2004)

Do radioiodine-avid lymph nodes from differentiated thyroid cancer on the initial posttherapy scan need repeated 131I therapy?
by: Yongji Jiang, et al.
Published: (2023-05-01)

The diagnostic usefulness of FDG-PET/CT in detecting tumor recurrence not evident in whole body I131 scan in differentiated thyroid carcinoma
by: Maged Abdel Galil Hamed, et al.
Published: (2014-06-01)

Single photon emission computed tomography (SPECT)/computed tomography using Iodine-123 in patients with differentiated thyroid cancer: additional value over whole body planar imaging and SPECT.
by: Barwick, T, et al.
Published: (2010)

Stunning Australia
by: Fiona Probyn-Rapsey
Published: (2013-02-01)